LeonaBio Q3 net loss more than triples to $21.16 million
LONA•LeonaBio’s third-quarter 2026 net loss more than tripled year over year to $21.16 million, while cash, cash equivalents and investments fell 63% to $32.3 million at September 30.
1. Quarterly results
LeonaBio’s third-quarter 2026 net loss more than tripled year over year to $21.16 million. Research and development expenses rose to $15.02 million.
2. Cash and trial timing
Cash, cash equivalents and investments fell 63% to $32.3 million at September 30, 2026, from December 31, 2025. The company targets completing enrollment in its Phase 3 ELAINE-3 trial of lasofoxifene in the fourth quarter of 2026.




